April 3rd, 2011

2-Year Outcomes of the RESOLUTE All Comers Trial

The Resolute zotarolimus-eluting stent (ZES) is now starting to demonstrate good long-term results. At an interventional featured clinical study session at the ACC in New Orleans and in a simultaneous publication in the Lancet, Sigmund Silber and colleagues presented the 2-year findings of the RESOLUTE All Comers trial comparing the ZES with the Xience V everolimus-eluting stent (EES) in a broadly representative patient population. Previously, the 1-year results had shown that the ZES was noninferior to the EES with respect to the primary endpoint of cardiac death, target vessel MI, and ischemia-driven target lesion revascularization.

More than 2200 patients at 17 centres in Europe and Israel completed the 2-year follow-up. Patient-related events (all deaths,  MIs, and revascularizations) occurred equally in both groups (20.6% of the ZES group and 20·5% of the EES group). Similarly, stent-related events (target lesion failure) occurred in 11·2% of the ZES group and 10·7% of the EES group (p=0·736). Three patients in each group had a stent thrombosis after 1 year.

The investigators point out that “the greater number of patient-related than stent-related events in patients with complex clinical and lesion characteristics emphasises that during long-term follow-up, the optimisation of secondary prevention is at least as important as the selection of which new generation drug-eluting stent to implant in a specific lesion.”

In an accompanying comment, Jens Lassen writes that “the most important take-home message of the 2-years result of the RESOLUTE All Comers trial is that the overall non-inferiority result was preserved even after cessation of dual antiplatelet therapy, and that the low rate of very late stent thrombosis seems to be achieved without a major increase in late target lesion revascularisations.”

For more of our ACC.11 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Roundup.

Comments are closed.